Topical sulindac therapy in diabetic senile cataracts: cataract-IV.

Article Details

Citation

Sharma YR, Vajpayee RB, Bhatnagar R, Mohan M, Azad RV, Kumar M, Nath R

Topical sulindac therapy in diabetic senile cataracts: cataract-IV.

Indian J Ophthalmol. 1989 Jul-Sep;37(3):127-33.

PubMed ID
2632448 [ View in PubMed
]
Abstract

Sulindac, a non-steroidal anti-inflammatory drug has been found to be a potent inhibitor of enzyme aldose reductase. We used sulindac topically in diabetic senile cataract patients to note if it effects the progression of cataracts. More of sulindac treated eyes maintained initial vision and fewer eyes had visual loss of up to two lines or more as compared to control eyes. The extent and density of different opacities showed less progression in sulindac treated eyes but it was not statistically significant except that the ophthalmoscopically observed density of opacity showed statistically very significant lesser mean increase in sulindac treated eyes. We suggest that sulindac is a potential drug which should be further evaluated in large double blind photodocumented studies in diabetic senile cataracts.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
SulindacAldose reductaseProteinHumans
Unknown
Inhibitor
Details